History
An Oklahoma and Texas oil explorer walked away from oil and gas, became a real estate, medical products and pharma group tied to its chairman's Beechwood, and by 2022 had no auditor.
2011-2015: A small oil explorer steps back
The company, then called Independence Energy Corp. (renamed from Oliver Creek Resources in 2008), began its oil and gas push in December 2011, buying a 5% interest in the Quinlan Lease in Pottawatomie County, Oklahoma. It said it began earning revenue from the operating well there. In March 2012 it paid $115,000 for a 5% working interest in a two-well drilling program in Coleman County, Texas, with MontCrest Energy, and in June 2012 it bought a 12.5% working interest in about 2,421 acres there for $90,784.50. In May 2012 it also arranged for one investor to advance up to $1,000,000, paid for with new shares priced at 90% of a recent average price. Shares on issue rose from 24,000,000 at the end of 2011 to 121,804,155 a year later.
In February 2013 the company settled with MontCrest and Black Strata, handing back its well interests in return for a 100% interest in about 1,400 acres of the Coleman County South Lease. The filing did not say why. In April 2014 those leases were allowed to expire, because management chose to focus on medical device distribution after an Asset Purchase Agreement with American Medical Distributors. In November 2014 it sold 14,905,918 shares and warrants to two investors for $50,000. In August 2015 its Oklahoma well interests were assigned to operator Nitro Petroleum for $10, ending its oil and gas involvement. The same announcement said the name would change to RedHawk Holdings Corp.
2015-2017: Beechwood, real estate and medical devices
From late 2015 the company moved into real estate and medical products, largely through dealings with Beechwood Properties, controlled by chairman and CFO G. Darcy Klug. It created Series A and Series B convertible preferred stock, and used them to buy commercial real estate, a Youngsville rental property and units in the Towers Hotels Fund 2013 from Beechwood, as well as about $1.86 million of cash and securities. It also took on bank debt and a Regions Bank line of credit. In December 2015 it acquired the Disintegrator needle destruction unit and the Carotid Artery Non-Contact Thermometer from Big Horse Holdings and Jason Roth for 60,000,000 restricted shares. Beechwood then owned about 55.8% of the common stock. In December 2017 its UK subsidiary, RedHawk Pharma, took a stake in EcoGen Europe, ending with about $545,000 of preference shares and 75% of the common shares; 10,000,000 RedHawk shares were returned to the company.
2019-2020: Settlement, swaps and dilution
In March 2019 the company settled lawsuits with former CEO Daniel Schreiber. He returned his 52,377,108 shares, and the company agreed to pay $250,000 plus two $200,000 notes. In June 2019 it bought back 113,700,000 shares from Beechwood for 1,277 Series A preferred shares and a warrant for 113,508,450 shares, while note holders converted $574,250 into 114,849,929 shares. In July 2019 it named Dr. Drew Pinsky spokesperson for its needle destruction devices, with a royalty and 68,700,000 shares, plus the same again a year later unless notice was given. In September 2019 it sold $500,000 of 7% convertible notes secured on real property, with warrants for 12,500,000 shares. In October and November 2020 it agreed to buy 124,849,365 and 122,730,903 common shares from Beechwood for Series B and Series A preferred stock, so the shares could be held for future issue. Shares on issue climbed from 483,593,867 at the end of 2018 to 1,217,032,870 at the end of 2020.
2021-2022: Property sales and no auditor
Auditor Postlethwaite & Netterville resigned on December 31, 2020, citing material weaknesses in internal controls; its reports for fiscal 2019 and 2020 carried going-concern doubt. MaloneBailey replaced it in January 2021. The company sold its former Youngsville headquarters for $256,000 in June 2021 and a Lafayette property for $450,000 in March 2022, repaying loans from the proceeds. In February 2022 it settled the Schreiber dispute for $150,000, with dismissal still to be confirmed by the court. It also added COVID test kits and blood collection tubes to its medical products.
On July 28, 2022, MaloneBailey resigned. As of August 3, 2022, the company had no auditor, had not filed its annual report for the year to June 30, 2021 or quarterly reports through March 2022, and set no timetable to catch up. It said it was weighing the cost of staying public.
Written from the 20 story beats below (2012 to 3 Aug 2022), which come from the company's own announcements and filings.